Novellia has launched its GLP-1 and Metabolic Health Registry to provide healthcare organisations with comprehensive real-world data on GLP-1 therapies. The registry draws from over 6,000 patients' clinical records, unified across every provider, payer and care setting, with each record spanning more than 20 years of continuous medical history. Early insights reveal that 81% of high-comorbidity patients achieved at least 5% weight loss, compared to 54% of low-comorbidity patients. Over 75% of enrolled patients carry high comorbidity burdens, including anxiety, depression and chronic pain. The New York-based company aims to address gaps in traditional clinical trials and claims data, which often lag behind patient care and underrepresent patients with multiple comorbidities. The registry continues to expand daily, providing visibility into treatment changes, coverage disruptions and real-world factors affecting patient outcomes.

Novellia raises $18M to scale patient-controlled medical data platform. Patient-controlled health data startup Novellia Inc. today announced it has raised $18 million in Series A funding to scale up a platform that lets patients consolidate their medical records and choose to share them with drug companies for research. The company also announced the launch of a patient-facing mobile app. Novellia operates what it calls the only real-world data company built entirely on information patients elect to contribute, positioning itself against third-party data brokers that assemble research datasets from insurance claims and hospital records. It says the current model leaves the patient out of the equation despite a market that runs above $50 billion a year. Novellia's platform pulls together as much as 20 years of medical history from disparate hospital systems, doctors' offices and labs across the U.S. in under 30 seconds. The company says the tool is particularly aimed at people managing serious or complex conditions, who typically spend hours chasing down records and repeating their histories to new providers. Once records are consolidated, Novellia applies natural language processing models to extract structured signals from unstructured clinical text, including physician notes, lab narratives and diagnostic reports. The company says that material is often the richest layer of a medical record and the hardest for existing data vendors to access. The output is de-identified into datasets that pharmaceutical companies use for research. Novellia counts several of the top 10 pharmaceutical companies and a number of early-stage diagnostics firms among its customers. According to the company, it has signed seven-figure, multiyear contracts with some of the largest drugmakers in the world since the Series A closed. "Behind every patient is a fragmented, incomplete record of their life," said co-founder and Chief Executive Shashi Shankar. "I watched this up close: first through my grandfather's cancer journey and then professionally in pharma, where we were developing therapies without ever seeing the full picture." The newly launched mobile app extends Novellia's existing web platform, giving individuals a free way to access and organize their full health history from a phone. The company has cited research showing close to 70% of patients are willing to contribute data for medical research if they are given control, transparency and privacy protections. The Series A was led by Spark Capital, with participation from Khosla Ventures, Acrew Capital, Bling Capital and TMV. "For a long time, I looked for a company like Novellia," said Alex Finkelstein, general partner at Spark Capital. "Shashi understood the problem firsthand and built the solution that benefits patients and research." Novellia is based in New York. The new round takes its total funding to $28 million. Image: Novellia. A message from John Furrier, co-founder of SiliconANGLE: Support its mission to keep content open and free by engaging with theCUBE community. Join theCUBE's Alumni Trust Network, where technology leaders connect, share intelligence and create opportunities. * 15M+ viewers of theCUBE videos, powering conversations across AI, cloud, cybersecurity and more * 11.4k+ theCUBE alumni - Connect with more than 11,400 tech and business leaders shaping the future through a unique trusted-based network. About SiliconANGLE Media SiliconANGLE Media is a recognized leader in digital media innovation, uniting breakthrough technology, strategic insights and real-time audience engagement. As the parent company of SiliconANGLE, theCUBE Network, theCUBE Research, CUBE365, theCUBE AI and theCUBE SuperStudios - with flagship locations in Silicon Valley and the New York Stock Exchange - SiliconANGLE Media operates at the intersection of media, technology and AI. Founded by tech visionaries John Furrier and Dave Vellante, SiliconANGLE Media has built a dynamic ecosystem of industry-leading digital media brands that reach 15+ million elite tech professionals. Its new proprietary theCUBE AI Video Cloud is breaking ground in audience interaction, leveraging theCUBEai.com neural network to help technology companies make data-driven decisions and stay at the forefront of industry conversations.